



DEPARTMENT OF HEALTH & HUMAN SERVICES

APR 18 2005

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Ms. Lorna Gamboa
Regulatory Affairs and
Quality Affairs Manager
Varian, Inc.
25200 Commercentre Drive
Lake Forest, California 92630

Re: k050321
Trade/Device Name: Varian, Inc. On Trak TesTcard 9
Regulation Number: 21 CFR § 862.3100
Regulation Name: Amphetamine Test System
Regulatory Class: II
Product Code: DKZ, DIS, JXM, DIO, LAF, DJJ, LCM, LFG, LDJ
Dated: February 3, 2005
Received: February 9, 2005

Dear Ms. Gamboa:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (240)276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>

Sincerely yours,

A handwritten signature in cursive script that reads "Jean M. Cooper MS, DVM".

Jean M. Cooper, MS, D.V.M.
Director
Division of Chemistry and Toxicology
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number: K050321

Device Name: On Trak TesTcard 9

Indications For Use: K050321

On Trak TesTcard 9 product, is an in vitro diagnostic test intended for use by health care professionals only for the qualitative detection of drug or drug metabolites in urine. On Trak TesTcard 9 simultaneously tests for the presence of multiple drugs or drug metabolites at or above the stated concentrations.

Cutoff Concentrations:

Amphetamines	1000 ng/mL	Morphine	300 ng/mL
Barbiturates	200 ng/mL	Phencyclidine (PCP)	25 ng/mL
Benzodiazepines	100 ng/mL	Tricyclic Antidepressants (TCA)	1000 ng/mL
Cocaine metabolite	300 ng/mL	Tetrahydrocannabinols (THC)	50 ng/mL
Methamphetamine	500 ng/mL		

Prescription Use √

AND/OR

Over-The-Counter Use

(Part 21 CFR 801 Subpart D)

(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Page 1 of 2

Carol C Benson
Division Sign-Off

Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K050321

On Trak TesTcard 9 product provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmation method. Clinical consideration and professional judgment should be applied to any drug abuse test result, particularly when preliminary positive results are used.

Carol Benson
Division Sign-Off

Office of In Vitro Diagnostic
Device Evaluation and Safety

6/10/10 K05 0321